New shot aims to reverse HPV-linked cervical damage
NCT ID NCT07175662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental treatment called NWRD08 in 150 women with high-grade cervical lesions (CIN2/3) caused by HPV types 16 or 18. The treatment is given as a shot followed by a quick electrical pulse to help it enter cells. The goal is to see if it can shrink or eliminate the abnormal cells. Participants are randomly assigned to receive either the active treatment or a placebo, and neither they nor their doctors will know which they received.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) ASSOCIATED WITH HUMAN PAPILLOMAVIRUS (HPV) 16 AND/OR HPV18 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Obstetrics and Gynecology Hospital
RECRUITINGBeijing, Beijing Municipality, 100026, China
-
Cancer Institute and Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
-
The Second Hospital of Shanxi Medical University
RECRUITINGTaiyuan, Shanxi, 030001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.